Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Cytotoxic chemotherapy
1 evidence topic · 2 sources
Zanzalintinib (XL092)
Metastatic colorectal cancer
- Manufacturer
- Exelixis
- Regulatory submission
- NDA submitted December 2025
- Launch
- Not announced
- Last updated